<DOC>
	<DOCNO>NCT01201356</DOCNO>
	<brief_summary>The purpose study collect long-term safety tolerability , long-term efficacy , health outcome data patient currently ongoing fingolimod multiple sclerosis clinical development program . This study combine currently ongoing Phase II III fingolimod extension study well ongoing newly plan study one single long-term extension protocol provide patient continuous treatment continue fingolimod register , commercially available , reimburse respective country .</brief_summary>
	<brief_title>Long-term Safety Tolerability 0.5 mg Fingolimod Patients With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients complete select ongoing planned trial FTY720 . Premature permanent discontinuation previous fingolimod study . Pregnant nursing ( lactate ) woman . Women childbearing potential , UNLESS use two birth control method , least 1 must hormonal contraception , tubal sterilization , partner 's vasectomy intrauterine device . Chronic disease immune system , multiple sclerosis , may require immunosuppressive treatment . Diabetic patient moderate severe nonproliferative diabetic retinopathy proliferative diabetic retinopathy uncontrolled diabetic patient HbA1c &gt; 8 % . Active systemic bacterial , viral fungal infection , know AIDS , Hepatitis B , Hepatitis C infection positive HIV antibody , Hepatitis B surface antigen Hepatitis C antibody test . Previous treatment cladribine , cyclophosphamide mitoxantrone . Treatment immunoglobulins and/or monoclonal antibody ( include Natalizumab ) past 3 month previous fingolimod study : Any following cardiovascular condition develop previous fingolimod study : Myocardial infarction within past 6 month prior entry extension study current unstable ischemic heart disease ; Cardiac failure ( Class III , accord New York Heart Association Classification ) severe cardiac disease determine investigator ; Arrhythmia require current treatment Class III antiarrhythmic drug ( e.g. , amiodarone , bretylium , sotalol , ibutilide , azimilide , dofetilide ) History presence third degree AV block Proven history sick sinus syndrome sinoatrial heart block Known history angina pectoris due coronary spasm Raynaud 's phenomenon Any follow pulmonary condition previous fingolimod study : Severe respiratory disease pulmonary fibrosis diagnose ( previous fingolimod study ) Active tuberculosis Alcohol abuse , chronic liver disease previous fingolimod study . The patient must participate previous fingolimod trial eligible participate trial . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Fingolimod</keyword>
	<keyword>FTY720</keyword>
	<keyword>Relapsing form MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Efficacy</keyword>
</DOC>